HAART in HIV/AIDS Treatments: Future Trends

Infect Disord Drug Targets. 2018;18(1):15-22. doi: 10.2174/1871526517666170505122800.


AIDS (acquired immune deficient syndrome) is a deadly human viral infectious disease caused by HIV (human immune-deficient virus) infection. Almost every AIDS patient losses his/her life before mid 1990s. AIDS was once the 1st disease killer in US (1993). After one decade hard work, antiviral drug cocktails-high active anti-retroviral therapy (HAART) have been invented for almost all HIV infection treatments. Due to the invention of HAART, 80-90% HIV/AIDS patients still effectively response to HAART for deadly AIDS episode controls and life saving. Yet, this type of HIV therapeutics is incurable. HIV/AIDS patients need to take HAART medications regularly and even life-long. To counteract this therapeutic drawback, more revolutionary efforts (different angles of therapeutic modes/attempts) are urgently needed. In this article, the major progresses and drawbacks of HIV/AIDS chemotherapy (HAART) to HIV/AIDS patients have been discussed. Future trends (updating pathogenesis study, next generations of drug developments, new drug target discovery, different scientific disciplinary and so on) are highlighted.

Keywords: HAART; HIV cure; HIV latency; HIV reservoirs; antiviral therapy; biotherapy; drug delivery system; integrase inhibitors; medicinal chemistry; pharmacogenomics.

Publication types

  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / virology
  • Anti-HIV Agents / isolation & purification
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / methods
  • Antiretroviral Therapy, Highly Active / trends*
  • Chemistry, Pharmaceutical / methods
  • Disease Reservoirs / virology
  • Drug Delivery Systems
  • Drug Discovery / trends*
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Pharmacogenetics / methods
  • Pharmacogenetics / trends


  • Anti-HIV Agents